This report analyzes the venture capital (VC) investment activity in Q1 2026 in the Pharma sector.
In Q1 2026, global pharma investment totaled $7.9 billion, down 19.6% from Q4 2025. Deal volume also fell by 19.6% to 180 transactions. Oncology emerged as the top therapy area with 86 deals backed by 322 investors.
In Q1 2026, global pharma investment totaled $7.9 billion, down 19.6% from Q4 2025. Deal volume also fell by 19.6% to 180 transactions. Oncology emerged as the top therapy area with 86 deals backed by 322 investors.
Report Scope
- This report provides an overview of VC investment activity globally in Q1 2026 in the Pharma sector involving biopharmaceutical drug companies.
- It identifies key trends, and the most notable deals announced in Q1 2026 in the Pharma sector.
Reasons to Buy
- Companies that strategically invest in venture funding position themselves for success, while those that fail to adapt risk falling behind.
- This report provides an overview of global VC investment trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.
Table of Contents
1 Table of Contents1.1 List of Tables
1.2 List of Figures
2 Pharma VC Investment Trends in Q1 2026
3 Global Investment Trends in Pharma
4 Global Quarterly Funding Activity in Pharma
5 Global VC Investment Trends for Biotechs
6 Top VC Investments in Pharma Q1 2026
7 Global Mega VC Investment Trends in Pharma
8 Global Quarterly Mega VC Investment Trends in Pharma
9 Global VC Investment in Pharma by Deal Size Analysis
10 Global VC Investment in Pharma by Funding Stage Analysis
11 Global VC Investment Trends in Pharma by Top Deal Stage
12 Regional VC Investment Comparison in Pharma - Q1 2026
13 Regional VC Investment in Pharma by Value and Volume
14 VC Investment Analysis in Pharma by Top 10 Countries
15 VC Investment Analysis in Pharma by 10 Therapy Areas
16 Top VC Investors in Pharma by Value in Q1 2026
17 Further Information
17.1 Methodology
18 Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Earendil Labs
- Parabilis Medicines
- CORXEL Pharmaceuticals (Shanghai)
- Mirador Therapeutics
- Soley Therapeutics
- Alveus Therapeutics
- Syneron Bio
- Angitia Biopharmaceuticals
- Slate Medicines
- Diagonal Therapeutics
- Ambrosia Biosciences
- Altesa Biosciences
